Repare in progress

Synthetic lethality play Repare emerges from stealth with $68M series A

With a $68 million series A co-led by Versant Ventures and MPM Capital, Repare Therapeutics Inc. emerged from 18 months of stealth today, making a splash in the growing pool of newcos targeting cancer via synthetic lethality. The company thinks its CRISPR screening platform will yield a deep, well-validated pipeline that could bring two lead compounds to the clinic in 2019.

Synthetic lethality occurs when deficiencies

Read the full 669 word article

User Sign In